《新股消息》(方土方)博醫療(02216.HK)今起招股 入場費9,444.22元
(方土方)博醫療(02216.HK)公布,於9月13至16日招股,發行8,935.5萬股股份,其中10%股份在港作公開發售,其餘為國際配售。每股發售價介乎17.2元至18.7元,每手500股,入場費為9,444.22元。預計股份於本月24日掛牌上市。高盛、海通為聯席保薦人。
公司獲10名基石投資者認購合共9,100萬美元金額,當中包括UBS AM Singapore、Lake Bleu Prime、雪湖資本、CEPHEI、Summer Healthcare Fund、Springhill Master Fund Limited、Artisan China Post-Venture Fund、Valliance Fund、Emerging Fund、Worldwide Fund。
按招股價中位數17.95元計算,料集資淨額為14.88億元,其中49.9%用於核心產品研發和商業上市提供資金;21%用於RF-II正在進行及計劃的研發和商業上市提供資金;18.5%用於其他產品及候選產品;9.2%用於擴大生產廠房的生產線提供資金;13.2%用於通過潛在收購持續擴大產品組合提供資金;9.2%用於營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.